Results of TRODELVY® real-world data

ASH 2024

Lymphoma

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

SPECIAL REPORT

Lymphoma

Real-World Comparison of YESCARTA^® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL

Skin Cancer

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

Eur J Cancer

Amaral T, Nanz L, Higuita LMS, Ascierto P, Berking C, Couselo EM, Donia M, Dummer R, Gutzmer R, Haushild A, Jalving M, Lee R, Lorigan P, Marquez-Rodas I, Michelin O, Nathan P, Robert C, Schadendorf D, Sobczuk P, Flatz L, Leiter U, Garbe C

doi: 10.1016/j.ejca.2024.115160

Further Publications

A Real-world Toxicity Atlas Shows that Adverse Events of Combination Therapies Commonly Result in Additive Interactions

Clin Cancer Res

Küçükosmanoglu A, Scoarta S, Houweling M, Spinu N, Wijnands T, Geerdink N, Meskers C, Kanev GK, Kiewiet B, Kouwenhoven M, Noske D, Wurdinger T, Pouwer M, Wolff M, Westerman BA

doi: 10.1158/1078-0432.CCR-23-0914

ASH 2024

Lymphoma

Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

Multiple Myeloma (MM)

Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis

Leuk Lymphoma

Varma G, Fogel L, Gordon B, Saldarriaga MM, Ahn J, Aleman A, Caro J, Rosenberg MC, Monge J, Parmar H, Kaminetzky D, Moskovits T, Siegel DS, Morgan GJ, Niesvizky R, Davies FE, Biran N

doi: 10.1080/10428194.2024.2446617

Gastrointestinal Cancer

Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data

Cancer Immunol Immunother

Reimann P, Mavroeidi IA, Burghofer J, Taghizadeh H, Webersinke G, Kasper S, Schreil G, Morariu D, Reichinger A, Baba HA, Kirchweger P, Schuler M, Djanani A, Prager GW, Rumpold H, Benda M, Schneider EM, Mink S, Winder T, Doleschal B

doi: 10.1007/s00262-024-03842-y

Genitourinary Cancer

Real-world treatment patterns and medical costs of prostate cancer patients in Switzerland - A claims data analysis

Eur J Cancer

Stucki M, Dosch S, Gnädinger M, Graber SM, Huber CA, Lenzin G, Strebel RT, Zwahlen DR, Omlin A, Wieser S

doi: 10.1016/j.ejca.2024.114072

Further Publications

Comprehensive Genome Profiling for Treatment Decisions in Patients with Metastatic Tumors: Real-World Evidence Meta-Analysis and Registry Data Implementation

J Natl Cancer Inst

Zerdes I, Filis P, Fountoukidis G, El-Naggar AI, Kalofonou F, D'Alessio A, Pouptsis A, Foukakis T, Pentheroudakis G, Ahlgren J, Smith D, Valachis A

doi: 10.1093/jnci/djaf015

Oncology · Hematology

Results of TRODELVY^® real-world data

Related content

Liso-cel is effective and safe in a broad real-world population of R/R LBCLa patients, including second-line setting and secondary CNS involvement

Real-World Comparison of YESCARTA® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

A Real-world Toxicity Atlas Shows that Adverse Events of Combination Therapies Commonly Result in Additive Interactions

Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis

Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data

Real-world treatment patterns and medical costs of prostate cancer patients in Switzerland - A claims data analysis

Comprehensive Genome Profiling for Treatment Decisions in Patients with Metastatic Tumors: Real-World Evidence Meta-Analysis and Registry Data Implementation

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

Real-World Comparison of YESCARTA^® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL